March 2014: Mutabilis joins MEDICEN
The global competitiveness cluster specializing in innovative technologies for health and new therapies.
READ MOREThe global competitiveness cluster specializing in innovative technologies for health and new therapies.
READ MORE“Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage.”
READ MORE“Vectorization efforts to increase Gram-negative intracellular drug concentration: a case study on HldE-K inhibitors.”
READ MORE“Novel HldE-K inhibitors leading to attenuated Gram negative bacterial virulence.”
READ MORE“Structural-functional studies of Burkholderia cenocepacia D-glycero-β-D-manno-heptose 7-phosphate kinase (HldA) and characterization of inhibitors with antibiotic adjuvant and antivirulence properties.”
READ MORE